tradingkey.logo

BRIEF-Bristol Myers Squibb Announces Opdivo Plus Chemotherapy As The Only Therapy To Demonstrate Overall Survival In Resectable Non-Small Cell Lung Cancer

ReutersFeb 19, 2025 12:08 PM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES OPDIVO® PLUS CHEMOTHERAPY AS THE FIRST AND ONLY NEOADJUVANT-ONLY IMMUNO-ONCOLOGY THERAPY TO DEMONSTRATE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OVERALL SURVIVAL IN RESECTABLE NON-SMALL CELL LUNG CANCER

  • BRISTOL-MYERS SQUIBB CO - STUDY SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL WITH OPDIVO PLUS CHEMOTHERAPY

  • BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY SIGNALS OBSERVED WITH OPDIVO PLUS CHEMOTHERAPY

Source text: ID:nBw3XKR9ga

Further company coverage: BMY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI